[
PSMA-HYNIC ligands
PSMA-T4
in vitro
in vivo
kit formulation development
preclinical study
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
25 Oct 2022
25 Oct 2022
Historique:
received:
16
09
2022
revised:
11
10
2022
accepted:
21
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
Despite significant advances in nuclear medicine for diagnosing and treating prostate cancer (PCa), research into new ligands with increasingly better biological properties is still ongoing. Prostate-specific membrane antigen (PSMA) ligands show great potential as radioisotope carriers for the diagnosis and therapy of patients with metastatic PCa. PSMA is expressed in most types of prostate cancer, and its expression is increased in poorly differentiated, metastatic, and hormone-refractory cancers; therefore, it may be a valuable target for the development of radiopharmaceuticals and radioligands, such as urea PSMA inhibitors, for the precise diagnosis, staging, and treatment of prostate cancer. Four developed PSMA-HYNIC inhibitors for technetium-99m labeling and subsequent diagnosis were subjected to preclinical in vitro and in vivo studies to evaluate and compare their diagnostic properties. Among the studied compounds, the PSMA-T4 (Glu-CO-Lys-L-Trp-4-Amc-HYNIC) inhibitor showed the best biological properties for the diagnosis of PCa metastases. [
Identifiants
pubmed: 36364046
pii: molecules27217216
doi: 10.3390/molecules27217216
pmc: PMC9658561
pii:
doi:
Substances chimiques
Ligands
0
Antigens, Surface
0
Technetium
7440-26-8
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Med Chem. 2008 Aug 14;51(15):4504-17
pubmed: 18637669
J Biol Chem. 1990 Dec 5;265(34):21297-301
pubmed: 2250024
Pharmaceuticals (Basel). 2021 Oct 29;14(11):
pubmed: 34832889
Radiology. 2007 Apr;243(1):28-53
pubmed: 17392247
J Nucl Med. 2017 Oct;58(10):1545-1552
pubmed: 28687599
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688
pubmed: 27889802
World J Nucl Med. 2017 Jan-Mar;16(1):3-7
pubmed: 28217012
Medicine (Baltimore). 2019 Oct;98(40):e17451
pubmed: 31577771
EJNMMI Res. 2018 Aug 22;8(1):84
pubmed: 30136051
Mol Pharm. 2009 May-Jun;6(3):790-800
pubmed: 19361232
J Nucl Med. 2015 Jun;56(6):914-20
pubmed: 25883127
Cancer Res. 2009 Sep 1;69(17):6932-40
pubmed: 19706750
J Biol Chem. 1987 Oct 25;262(30):14498-506
pubmed: 3667587
J Neurochem. 1988 Apr;50(4):1200-9
pubmed: 3346674
Lancet. 2016 Jan 2;387(10013):70-82
pubmed: 26074382
J Cell Biochem. 2004 Feb 15;91(3):528-39
pubmed: 14755683
Asian J Androl. 2013 May;15(3):309-13
pubmed: 23564043
Nucl Med Biol. 2017 May;48:36-44
pubmed: 28193503
J Neurochem. 1993 May;60(5):1631-8
pubmed: 8097231
Oncotarget. 2019 Mar 29;10(25):2451-2461
pubmed: 31069008
Clin Cancer Res. 1996 Sep;2(9):1445-51
pubmed: 9816319
J Med Chem. 2016 Mar 10;59(5):1761-75
pubmed: 26878194
EJNMMI Res. 2019 Jun 3;9(1):52
pubmed: 31161459
J Nucl Med. 2017 Sep;58(9):1442-1449
pubmed: 28450562
Mol Imaging Radionucl Ther. 2017 Jun 1;26(2):62-68
pubmed: 28613198
Appl Radiat Isot. 2001 Feb;54(2):203-8
pubmed: 11200881
Hum Pathol. 2007 May;38(5):696-701
pubmed: 17320151
Mol Imaging Biol. 2003 Nov-Dec;5(6):376-89
pubmed: 14667492
Bioconjug Chem. 2012 Apr 18;23(4):688-97
pubmed: 22369515
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209
pubmed: 25411132
Rev Assoc Med Bras (1992). 2017 Aug;63(8):722-725
pubmed: 28977112
Brain Res. 1998 Jun 8;795(1-2):341-8
pubmed: 9622670
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
Molecules. 2022 Apr 19;27(9):
pubmed: 35565970
J Med Chem. 2013 Aug 8;56(15):6108-21
pubmed: 23799782
Nucl Med Biol. 2017 May;48:69-75
pubmed: 28273495
Molecules. 2017 Mar 24;22(4):
pubmed: 28338640
Pharmaceuticals (Basel). 2014 Jun 30;7(7):779-96
pubmed: 24983957
Int J Mol Sci. 2021 Mar 08;22(5):
pubmed: 33800517
Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1085-6
pubmed: 22310854
J Nucl Med. 2017 Feb;58(2):235-242
pubmed: 27635024
Can J Urol. 2008 Dec;15(6):4363-74
pubmed: 19046489
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541
Asian J Urol. 2019 Apr;6(2):129-136
pubmed: 31061798
Eur J Pharmacol. 2001 Sep 14;427(2):91-6
pubmed: 11557259
PLoS Biol. 2020 Jul 14;18(7):e3000411
pubmed: 32663221
Adv Urol. 2009;:818065
pubmed: 20339583
Peptides. 2005 Feb;26(2):295-9
pubmed: 15629541
BJU Int. 2014 Sep;114(3):323-5
pubmed: 24981126
J Nucl Med. 2013 Aug;54(8):1369-76
pubmed: 23733925
J Med Chem. 2009 Jan 22;52(2):347-57
pubmed: 19111054